Research programme: interferon-beta stimulant - InDex PharmaceuticalsAlternative Names: DIMS 9054
Latest Information Update: 16 Jul 2016
At a glance
- Originator InDex Pharmaceuticals
- Class Oligonucleotides
- Mechanism of Action Interferon beta stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation; Pneumonia
- No development reported Multiple sclerosis